| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Pär I Johansson | Q30510274 |
| Sisse R Ostrowski | Q55704441 | ||
| P2093 | author name string | Sisse R Ostrowski | |
| P2860 | cites work | AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER. | Q34257237 |
| WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING. | Q34257361 | ||
| Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography | Q34469949 | ||
| Thrombin generation and fibrin clot structure | Q34598931 | ||
| Endothelial cell apoptosis in sepsis | Q34633543 | ||
| Evolving role of tissue factor and its pathway inhibitor | Q34633564 | ||
| Inhibitors: resolving diagnostic and therapeutic dilemmas | Q34636988 | ||
| Haemophilia care then, now and in the future | Q34916275 | ||
| The incidence of inhibitor development according to specific mutations - and treatment? | Q35563619 | ||
| Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors | Q35771690 | ||
| Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review | Q36244563 | ||
| Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography | Q36283835 | ||
| The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies | Q78981048 | ||
| Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity | Q80804341 | ||
| POSTOPERATIVE THROMBO-EMBOLIZATION: THE PLATELET COUNT AND THE PROTHROMBIN TIME AFTER SURGICAL OPERATIONS: A SIMPLE METHOD FOR DETECTING REDUCTIONS AND ELEVATIONS OF THE PROTHROMBIN CONCENTRATION (OR ACTIVITY) OF THE BLOOD PLASMA | Q81259721 | ||
| Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial | Q81445915 | ||
| Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial | Q83120299 | ||
| Transfusion packages for massively bleeding patients: the effect on clot formation and stability as evaluated by Thrombelastograph (TEG). | Q50644231 | ||
| Variability of prothrombin time and activated partial thromboplastin time in the diagnosis of increased surgical bleeding. | Q51478890 | ||
| Patterns of coagulopathy during liver transplantation: experience with the first 75 cases using thrombelastography. | Q51618184 | ||
| Predictive value of blood clotting tests in cardiac surgical patients. | Q51630153 | ||
| Predictive model for survival at the conclusion of a damage control laparotomy. | Q52068451 | ||
| Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. | Q52224502 | ||
| Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. | Q53940134 | ||
| Platelet procoagulant complex assembly in a tissue factor-initiated system | Q61405846 | ||
| Acute traumatic coagulopathy | Q73544166 | ||
| Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity | Q73553840 | ||
| Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding | Q77095125 | ||
| Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery | Q77647750 | ||
| What does it take to make the perfect clot? | Q36299261 | ||
| Total joint replacement in patients with inhibitors | Q36473080 | ||
| Mechanism of action, development and clinical experience of recombinant FVIIa | Q36477254 | ||
| Dose titration of recombinant factor VIIa using thromboelastograph monitoring in a child with hemophilia and high titer inhibitors to factor VIII: a case report and brief review | Q36646985 | ||
| Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: a review of the literature | Q37032862 | ||
| Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents | Q37082212 | ||
| Effect of Haemostatic Control Resuscitation on mortality in massively bleeding patients: a before and after study | Q37155308 | ||
| Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors | Q37236471 | ||
| Thrombelastography and tromboelastometry in assessing coagulopathy in trauma. | Q37379818 | ||
| The use of recombinant activated factor VII in platelet disorders: a critical review of the literature | Q37416007 | ||
| Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres. | Q39306120 | ||
| Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation | Q42137593 | ||
| A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study | Q42598903 | ||
| Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients | Q42686165 | ||
| Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products | Q43535398 | ||
| FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre | Q44045512 | ||
| Usefulness of thrombelastography in assessment of trauma patient coagulation | Q45104509 | ||
| Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group | Q45854984 | ||
| A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors | Q45855313 | ||
| Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention | Q45856532 | ||
| A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group | Q45856561 | ||
| Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97. | Q45857420 | ||
| A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation | Q45858938 | ||
| A retrospective postlicensure survey of FEIBA efficacy and safety. | Q45859618 | ||
| Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A. | Q45862449 | ||
| The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial | Q45864000 | ||
| Elective orthopaedic surgery for inhibitor patients | Q45869001 | ||
| Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors | Q45870481 | ||
| A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group | Q45870861 | ||
| Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. | Q45871220 | ||
| European study on orthopaedic status of haemophilia patients with inhibitors | Q45871281 | ||
| Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison | Q45873703 | ||
| Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency | Q45876419 | ||
| Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII. | Q45879514 | ||
| Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures | Q45879802 | ||
| Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. | Q45882175 | ||
| Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors | Q45883290 | ||
| Platelet activity of high-dose factor VIIa is independent of tissue factor | Q45884609 | ||
| Thrombelastography is better than PT, aPTT, and activated clotting time in detecting clinically relevant clotting abnormalities after hypothermia, hemorrhagic shock and resuscitation in pigs | Q46375354 | ||
| Early coagulopathy predicts mortality in trauma | Q47766285 | ||
| A reduction in clot formation rate and strength assessed by thrombelastography is indicative of transfusion requirements in patients with penetrating injuries | Q47785022 | ||
| Changes in transfusion therapy guided by thromboelastograph in cardiac surgery | Q48564290 | ||
| The kaolin-activated Thrombelastograph predicts bleeding after cardiac surgery | Q48675022 | ||
| An audit of red cell and blood product use after the institution of thromboelastometry in a cardiac intensive care unit | Q48721696 | ||
| Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. | Q49912954 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | enzyme | Q8047 |
| blood proteins | Q425056 | ||
| congenital disorder | Q727096 | ||
| hemophilia A | Q2092064 | ||
| supporting evidence | Q110632057 | ||
| P304 | page(s) | 107-116 | |
| P577 | publication date | 2010-07-21 | |
| P1433 | published in | Drug Design, Development and Therapy | Q2566724 |
| P1476 | title | Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders | |
| P478 | volume | 4 |
| Q38235951 | Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes |
| Q38024924 | Current management of massive hemorrhage in trauma. |
| Q24201292 | Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia |
| Q38739036 | Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries. |
| Q38007933 | Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. |
Search more.